TrialBMJ open gastroenterology2021

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.

Kathy Weisel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.